ABSTRACT

Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with promising activity in lymphoproliferative disorders and, in particular, in low-grade non-Hodgkin’s lymphoma (LG-NHL). Recently, a few reports have described interesting results using FLU in polychemotherapy regimens. In order to evaluate FLU in combination with other antineoplastic agents, we used a combination of FLU and idarubicin, called the FLU-ID regimen, to treat 10 patients with recurrent LG-NHL. The FLU-ID regimen was as follows: FLU 25 mg/sqm i.v. on days 1 to 3 and idarubicin 12 mg/sqm i.v. on day 1. Of the 10 patients, 2 (20%) achieved complete response (CR), 5 (50%) partial response, and the remaining 3 showed no benefit from the treatment. The 2 CR patients are still in remission after 6 and 8 months, respectively. The median duration of overall survival of all patients was 8 months. The major toxic effects observed were neutropenia (40%) and infections and/or febrile episodes (15%); no fatalities due to drug side effects occurred. These results indicate the efficacy of the FLU-ID regimen in inducing a good remission rate with moderate side effects in recurrent LG-NHL.

Key words: combination chemotherapy, fludarabine, idarubicin, recurrent LG-NHL
ment had failed to produce complete response or relapse had occurred.

Criteria for entry into the study included: histologic diagnosis of LG-NHL according to the updated Kiel classification; the presence of measurable disease; normal hepatic, renal, cardiac function; radiation and chemotherapy had to be discontinued at least 6 weeks before the start of treatment. Informed consent was obtained from all patients in accordance with the ethical policy of the Institute.

The FLU-ID regimen schedule was as follows: FLU 25 mg/sqm i.v. on days 1 to 3 and idarubicin 12 mg/sqm i.v. on day 1. FLU was supplied by Schering S.p.A. (Milan, Italy). Courses were given at 3-week intervals for a maximum of 6 cycles. All patients received bacterial and Pneumocystis carinii prophylaxis with co-trimoxazole (2 days per week) only during the entire course of therapy.

Patients were restaged after completion of 6 cycles. Clinical and pathologic evaluations were made by repeating radiographic investigations and bone marrow biopsy if previous results had been positive.

**Patient characteristics**

Of the 10 patients with LG-NHL, 6 were males and 4 females and the mean age was 55 years (range 40 to 64 years). Six patients had stage III and 4 stage IV disease; systemic symptoms were present in 3 patients.

The time from the initial diagnosis of LG-NHL to the start of the FLU-ID regimen ranged from 12 to 25 months (median 18 months). All these patients had previously received one (6 patients: 2 patients CHOP regimen, 2 CVP regimen, and 2 patients VNCOP-B protocol), or two (4 patients: 2 patients received CHOP and CVP, and 2 CVP and VNCOP-B) chemotherapy treatments. All the patients had recurrent, relapsed disease and none presented resistant disease; Table 1 depicts the pretreatment characteristics of the 10 patients.

**Response criteria**

Complete response (CR) was defined as a complete disappearance of signs and symptoms due to lymphoma that was maintained for at least 6 weeks; partial response (PR) was defined as a reduction of at least 50% in the product of two largest perpendicular diameters of all measurable lesions for a duration of at least 6 weeks. Standard Eastern Cooperative Group (ECOG) toxicity criteria were used.

**Results**

**Response**

Of the 10 patients studied, 2 fulfilled the criteria for CR and 5 for PR (70% overall response rate); the remaining 3 patients did not respond to the therapy. The likelihood of response correlated with the number of previous chemotherapy regimens. In fact, in the 6 patients who had previously received only one regimen, 2 CR and 2 PR were documented. In contrast, among the 4 patients who had received two different previous treatments, 3 PR were documented.

Concerning disease stage, we observed CR in 2 stage III patients; as for histology, the 2 CR patients presented centroblastic/centrocytic follicular lymphomas. Both complete responders had obtained a first CR with the induction treatment, and this remission had lasted for 9 and 11 months, respectively.

They are currently still in remission after 6 months; partial response (PR) was defined as a reduction of at least 50% in the product of two largest perpendicular diameters of all measurable lesions for a duration of at least 6 weeks. Standard Eastern Cooperative Group (ECOG) toxicity criteria were used.

**Table 1. Characteristics of 10 LG-NHL patients treated with the FLU-ID regimen.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. of patients</td>
<td>10</td>
</tr>
<tr>
<td>Median age (yr) (range)</td>
<td>55 (40-64)</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>6/4</td>
</tr>
<tr>
<td>Stage</td>
<td>III: 6; IV: 4</td>
</tr>
<tr>
<td>Histology*:</td>
<td>Cb/CC F: 6; Cb/Cc F &amp; D: 2; Ic: 2</td>
</tr>
<tr>
<td>Prior therapy:</td>
<td>1 treatment: 6; 2 treatments: 4</td>
</tr>
</tbody>
</table>

*Cb/CC F= centroblastic/centrocytic follicular; Cb/c F & D= centroblastic/centrocytic follicular and diffuse; Ic= immunocytoma lymphoplasmacytoid.
and 8 months, respectively. None of the other responses have been maintained. Among the partial responders, one progression was observed and this patient died from the disease. The median duration of overall survival of all patients was 8 months (range 6 to 16 months).

**Toxic effects**

The FLU-ID regimen was well tolerated in general, and all patients completed the therapy. With regard to hematologic toxicity, neutropenia was observed in 4 (40%) patients, 1 of whom reached grade 3 or 4 (neutrophil count less than $1 \times 10^9/L$), whereas thrombocytopenia, which was observed in 3 patients, was much less severe (grades 1 and 2) (platelet count between 50 and $100 \times 10^9/L$). Five (8%) of a total of 60 courses were temporarily postponed for one week because of neutropenia and/or thrombocytopenia, but no trend toward cumulative myelosuppression was observed.

Other major toxic effects were represented by infections; 1 episode of pneumonia and one moderately severe febrile episode in a neutropenic patient who showed negative cultures. No direct correlation was noted between the intensity of neutropenia after treatment and the incidence of febrile episodes. Cardiac, liver and renal side effects were not observed, and no fatalities due to drug side effects occurred.

**Discussion**

In this study, the 10 recurrent LG-NHL patients evaluated for response and toxicity to the FLU-ID regimen registered an overall response rate of 70%, with a CR rate of 20%.

LG-NHL continue to represent a challenge for hematologists. Patients with LG-NHL respond well and often achieve CR with conventional alkylating agent-based chemotherapy, but early relapses are frequent; only approximately 25% of patients are free of disease at 5 years. There is no standard therapy for patients who relapse after or become refractory to alkylating agents. Treatment options range from a watch and wait approach for asymptomatic patients to intensive high-dose chemo-radiotherapy with bone marrow or stem cell transplantation. Recently, FLU and 2-CdA, either alone or in combination with other drugs, have shown promising therapeutic activity of previously treated and untreated patients with LG-NHL. Our results with the FLU-ID regimen are encouraging and confirm those observed with fludarabine and mitoxantrone; in fact, we observed a higher overall response rate as well as a greater percentage of complete responders than that obtained with FLU alone. The toxic effects of this regimen were acceptable, with neutropenia and infections being the most prevalent problem.

The above studies on FLU alone indicate that this drug effectively induces remission in patients with LG-NHL, particularly those with follicular histology. However, as with other therapeutic modalities for LG-NHL, remission is rarely maintained beyond two years. On the basis of these data, a fludarabine-idarubicin combination-containing regimen is associated with a significantly higher overall response rate and complete response rate respect to with FLU alone in relapsed and advanced LG-NHL patients. Therefore these data indicate that FLU-ID-based regimens should be incorporated into first-line randomized trials of LG-NHL that compare fludarabine-containing schemes and other LG-NHL treatments, in order to evaluate possible advantages with regard to remission induction and duration of response.

**References**